Characteristics | Indomethacin group (N = 82) | Glycerin group (N = 84) | P |
---|---|---|---|
Female Male | 51 (62.19 %) 31 (37.80 %) | 59 (70.23 %) 25 (29.76 %) | 0.273 |
Age (years) | 51.59 ± 18.55 | 54.0 ± 17.85 | 0.394 |
Outpatients | 46 | 45 | 0.74 |
Hospitalized | 36 | 39 | |
Without comorbidity | 56 | 54 | 0.427 |
Comorbid conditions | 26 | 30 | |
Diabetes Mellitus type 2 | 12 | 14 | |
Hypertension | 7 | 7 | |
Dyslipidemia | 2 | 2 | |
Hypothyroidism | 1 | 0 | |
COPD | 1 | 1 | |
Hepatic cirrhosisa | 1 | 2 | |
Ischemic heart disease | 1 | 1 | |
HIV | 0 | 1 | |
Asthma | 1 | 2 | |
Normal total bilirubin pre-ERCP | 26 | 24 | 0.660 |
Elevated total bilirubin pre-ERCP | 56 | 60 | |
Previous cholecystectomy | 42 | 40 | 0.643 |
Dilated bile duct by imaging studies pre-ERCP | 56 | 62 | 0.506 |
Post-ERCP diagnostics | 0.35 | ||
Choledocolithiasis | 34 | 32 | |
Begin biliary stenosis and/or leakage | 18 | 14 | |
Suspected sphincter of Oddi dysfunction | 12 | 15 | |
Normal cholangiogram and/or pancreatogram | 8 | 11 | |
Malignant biliary tract stenosis | 8 | 9 | |
Pancreatic fistula | 2 | 3 | |
Pre-ERCP amylase level (U/L) | 57.39 ± 21.56 | 55.36 ± 20.77 | 0.540 |